CA2362004A1 - Proteines de fusion - Google Patents

Proteines de fusion Download PDF

Info

Publication number
CA2362004A1
CA2362004A1 CA002362004A CA2362004A CA2362004A1 CA 2362004 A1 CA2362004 A1 CA 2362004A1 CA 002362004 A CA002362004 A CA 002362004A CA 2362004 A CA2362004 A CA 2362004A CA 2362004 A1 CA2362004 A1 CA 2362004A1
Authority
CA
Canada
Prior art keywords
seq
group
adp
region
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002362004A
Other languages
English (en)
Inventor
Lisa Mckerracher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002362004A priority Critical patent/CA2362004A1/fr
Priority to CA2367636A priority patent/CA2367636C/fr
Priority to EP02721887A priority patent/EP1377319B1/fr
Priority to AU2002252867A priority patent/AU2002252867B2/en
Priority to AT02721887T priority patent/ATE480262T1/de
Priority to NZ528580A priority patent/NZ528580A/en
Priority to PCT/CA2002/000480 priority patent/WO2002083179A2/fr
Priority to DE60237589T priority patent/DE60237589D1/de
Priority to JP2002580980A priority patent/JP4489353B2/ja
Priority to US10/118,079 priority patent/US6855688B2/en
Publication of CA2362004A1 publication Critical patent/CA2362004A1/fr
Priority to US10/902,959 priority patent/US7442686B2/en
Priority to US10/902,878 priority patent/US20060134140A1/en
Priority to US11/643,940 priority patent/US20070270340A1/en
Priority to US11/808,773 priority patent/US7795218B2/en
Priority to US12/219,179 priority patent/US7910554B2/en
Priority to US12/329,918 priority patent/US20090142325A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
CA002362004A 2001-04-12 2001-11-13 Proteines de fusion Abandoned CA2362004A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CA002362004A CA2362004A1 (fr) 2001-04-12 2001-11-13 Proteines de fusion
CA2367636A CA2367636C (fr) 2001-04-12 2002-01-15 Proteines de fusion
DE60237589T DE60237589D1 (de) 2001-04-12 2002-04-08 Fusionsproteine
AU2002252867A AU2002252867B2 (en) 2001-04-12 2002-04-08 Fusion proteins
AT02721887T ATE480262T1 (de) 2001-04-12 2002-04-08 Fusionsproteine
NZ528580A NZ528580A (en) 2001-04-12 2002-04-08 Fusion proteins
PCT/CA2002/000480 WO2002083179A2 (fr) 2001-04-12 2002-04-08 Proteines de fusion
EP02721887A EP1377319B1 (fr) 2001-04-12 2002-04-08 Proteines de fusion
JP2002580980A JP4489353B2 (ja) 2001-04-12 2002-04-08 融合タンパク質
US10/118,079 US6855688B2 (en) 2001-04-12 2002-04-09 ADP-ribosyl transferase fusion proteins, pharmaceutical compositions, and methods of use
US10/902,959 US7442686B2 (en) 2001-04-12 2004-08-02 Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US10/902,878 US20060134140A1 (en) 2001-04-12 2004-08-02 Compositions and methods for treating tumor spreading
US11/643,940 US20070270340A1 (en) 2001-04-12 2006-12-22 ADP-ribosyl transferase fusion variant proteins
US11/808,773 US7795218B2 (en) 2001-04-12 2007-06-12 ADP-ribosyl transferase fusion variant proteins
US12/219,179 US7910554B2 (en) 2001-04-12 2008-10-14 Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US12/329,918 US20090142325A1 (en) 2001-04-12 2008-12-08 Compositions and methods for treating tumour spreading

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,342,970 2001-04-12
CA002342970A CA2342970A1 (fr) 2001-04-12 2001-04-12 Proteines de fusion
CA002362004A CA2362004A1 (fr) 2001-04-12 2001-11-13 Proteines de fusion

Publications (1)

Publication Number Publication Date
CA2362004A1 true CA2362004A1 (fr) 2002-10-12

Family

ID=4168763

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002342970A Abandoned CA2342970A1 (fr) 2001-04-12 2001-04-12 Proteines de fusion
CA002362004A Abandoned CA2362004A1 (fr) 2001-04-12 2001-11-13 Proteines de fusion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002342970A Abandoned CA2342970A1 (fr) 2001-04-12 2001-04-12 Proteines de fusion

Country Status (2)

Country Link
CA (2) CA2342970A1 (fr)
ES (1) ES2352654T3 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134140A1 (en) * 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions

Also Published As

Publication number Publication date
CA2342970A1 (fr) 2002-10-12
ES2352654T3 (es) 2011-02-22

Similar Documents

Publication Publication Date Title
CA2367636C (fr) Proteines de fusion
AU2002252867A1 (en) Fusion proteins
US7910554B2 (en) Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
AU2006341726B2 (en) Synthetic MeCP2 sequence for protein substitution therapy
Beerens et al. Protein transduction domains and their utility in gene therapy
EP2407536B1 (fr) Protéines variantes de fusion d'ADP-ribosyl transférase
US6800286B1 (en) Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
JPH09510352A (ja) 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
US20040110928A1 (en) Peptide conjugates for drug delivery
CN109563151A (zh) 用于治疗癌症的方法和组合物
KR20070051766A (ko) 클로스트리디움 보튤리넘 ｃ３ 엑소트랜스퍼라제 조성물 및이를 이용한 암전이 치료 방법
CA2362004A1 (fr) Proteines de fusion
US20070270340A1 (en) ADP-ribosyl transferase fusion variant proteins
RU2432359C2 (ru) ПРИМЕНЕНИЕ СЛИТОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО БЕЛОК MeCP2 И ДОМЕН ТРАНСДУКЦИИ БЕЛКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ТАКОЙ БЕЛОК, И СПОСОБ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ СВЯЗАННОГО С РАЗВИТИЕМ НЕРВНОГО ЗАБОЛЕВАНИЯ
KR102479847B1 (ko) 새로운 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
EP1605964B1 (fr) Vehicules de degradation de proteines cibles, constructions d'acides nucleiques codant pour ceux-ci et leur utilisation
KR102556731B1 (ko) 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
KR102146392B1 (ko) 포스포글리세레이트 뮤테이즈 1 융합단백질 및 이를 포함하는 약학 조성물
KR20240006722A (ko) 화물분자 수송 도메인 sy1, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
Beerens Intercellular spread of the transgene product to improve the efficiency of cancer gene therapy

Legal Events

Date Code Title Description
FZDE Dead